Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review

Zheng, Yan; Yao, Shuna; Liu, Yanyan; Zhang, Jianbo; Wang, Haiying; Chu, Junfeng; Yao, Zhihua

doi:10.3389/fonc.2020.608304

Cited by 19 publications

(18 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, HDAC inhibitors are now increasingly being used in combination with other types of anticancer drugs for the treatment of various malignancies. Chidamide is an innovative drug independently developed in China, which can exert anti-tumor activity by reversing tumor cell resistance, increasing tumor cell chemosensitivity, potently regulating immunity and potential direct anti-tumor effects[ 7 , 8 ]. In December 2014, chidamide was approved by China Food and Drug Administration for the treatment of relapsed or refractory peripheral T-cell lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report

He¹,

Yang²,

Zhou³

et al. 2022

WJCC

View full text Add to dashboard Cite

BACKGROUND Traditional chemotherapy has benefited many patients with non-Hodgkin's lymphoma, but results in a very poor response in patients with rare lymphomas or refractory lymphomas. Previous studies have shown that chidamide has potential anti-lymphoma activity and reverses lymphoma cell chemoresistance to increase the chemosensitivity of lymphoma cells to traditional chemotherapy. CASE SUMMARY A 14-year-old boy was admitted to our hospital with a 5-d history of generalized erythema, papules, and blisters. Initially, the disease was refractory to potent anti-allergic and anti-infective treatment, and his condition progressively worsened. Skin biopsy revealed primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Considering that the disease is extremely rare in clinical practice, existing case reports have shown poor efficacy with traditional chemotherapy alone. We recommend chidamide combined with traditional chemotherapy for treatment. The regimen was as follows: Chidamide 30 mg/biw, cyclophosphamide 1100 mg/d1, pirarubicin 70 mg/d1, vincristine 2 mg/d1, dexamethasone 20 mg/d1-5, etoposide 100 mg/d1-5, in a 21 d cycle. The treatment effect was considerable, and complete remission was achieved after 4 cycles of treatment, after which the patient completed a total of 6 cycles of treatment. Subsequently, the patient regularly took chidamide 20 mg/biw as maintenance therapy for 1 year. To date, the patient has been disease-free for 3 years. CONCLUSION This case suggests that the combination of chidamide and traditional chemotherapy is effective in primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report

He¹,

Yang²,

Zhou³

et al. 2022

WJCC

View full text Add to dashboard Cite

show abstract

“…In addition, chidamide could increase PD-L1 expression in the tumor microenvironment, and preclinical studies have demonstrated synergy between chidamide, and PD-1 blockade in solid tumors ( 55 , 57 ). A single-arm-phase II study is therefore currently ongoing to evaluate the activity of chidamide in combination with sintilimab in relapsed or refractory peripheral T-cell lymphomas ( 58 ). It is possible that chidamide administration in the context of these combination strategies could further enhance the killing of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

et al. 2021

View full text Add to dashboard Cite

The key factors leading to transformed follicular lymphoma (t-FL) include the aberrations of epigenetic modifiers as early and driving events, especially mutations in the gene encoding for histone acetyltransferase. Therefore, reversal of this phenomenon by histone deacetylase (HDAC) inhibitors is essential for the development of new treatment strategies in t-FL. Several t-FL cell lines were treated with various doses of chidamide and subjected to cell proliferation, apoptosis and cell cycle analyses with CCK-8 assay, Annexin V/PI assay and flow cytometry, respectively. Chidamide dose-dependently inhibited cell proliferation, caused G0/G1 cycle arrest and triggered apoptosis in t-FL cells. In addition, the effects of chidamide on tumor growth were evaluated in vivo in xenograft models. RNA-seq analysis revealed gene expression alterations involving the PI3K-AKT signaling pathway might account for the mechanism underlying the antitumor activity of chidamide as a single agent in t-FL. These findings provide a basis for further clinical exploration of chidamide as a promising treatment for FL.

show abstract

“…Although HDACi and PD-1 antibody have modest efficacy as a single agent, some published literature proved that PD-1 antibody and HDACi had synergistic effects in different kinds of tumor. Two case reports on NK/T cell lymphoma have reported that combined sintilimab and chidamide therapy may lead to successful outcomes ( 28 , 29 ). Moreover, a phase IB/II trial that included 38 patients with R/R extranodal NK/T cell lymphoma who were treated with sintilimab plus chidamide showed an ORR of 59.5% and a CR rate of 48.6% ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review

2021

View full text Add to dashboard Cite

Patients with relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been established for R/R tDLBCL. Herein we presented a single case of a patient with R/R tDLBCL who was successfully treated with sintilimab and chidamide. The patient was a 71-year-old man with pulmonary mucosa-associated lymphoid tissue lymphoma. He did not receive any treatment until tDLBCL was confirmed 2 years later. The tDLBCL was primary refractory to R2-CHOP, R2-MTX, and Gemox regimens. However, the patient achieved sustained complete remission after the combination therapy of sintilimab and chidamide. To the best of our knowledge, this is the first report of sintilimab combined with chidamide for the treatment of R/R tDLBCL, which opens up new therapeutic possibilities for this new combination therapy in future prospective clinical trials.

show abstract

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review

Cited by 19 publications

References 45 publications

Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report

Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review

Contact Info

Product

Resources

About